Two weeks before he announced CSL’s latest shock earnings downgrade, Gordon Naylor was scheduled to sit down with investors in Melbourne to brief them on the healthcare giant’s financial performance.

From blue-chip royalty to bin fire, the company’s staggering fall is a brutal reckoning for the Australian icon lost in its own complacency and hubris. Logic tells us worrying about round numbers in ...

Biotechnology business CSL, which specialises in bloods, vaccines and plasma products, flagged a US$5 billion (AU$6.9 billion) write-down of its assets. The Melbourne-headquartered company also ...

In a 90-day review, CSL told the market it would take another $US5bn ($A6.9bn) non-cash impairment. The first $1.5bn of this was recognised during the first-half ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Investors on Monday stripped billions from CSL’s market capitalisation, triggered by news of the impairment against its unpopular Vifor renal therapy acquisition, and the prospect of revenue and ...

Shares in health giant CSL tanked today, with the stock closing 16 per cent lower, at $100.75. At earlier points in the session, the stock was down more than 20 per cent, sinking below $100 to decade ...

CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. CSL (ASX:CSL) has outlined a restructuring plan that ...

April 23 (Reuters) - Australian biotech giant CSL extended losses on Thursday, lingering near decade lows, after the U.S. military scrapped its flu vaccine mandate, dealing ‌another blow to the ...

CSL shares are tumbling again on Wednesday. Here's what it'll take for the price to take a u-turn. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing ...